For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.


Amgen - Recent Press Releases
RSS Feeds RSS
DateTitle 
02/27/15Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal CancerPrinter Friendly Version
02/26/15Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple MyelomaPrinter Friendly Version
02/25/15Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving HemodialysisPrinter Friendly Version
02/25/15Amgen To Present At The Cowen And Company 35th Annual Health Care ConferencePrinter Friendly Version
02/11/15Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic MelanomaPrinter Friendly Version
02/03/15Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid ArthritisPrinter Friendly Version
01/29/15Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial HypercholesterolemiaPrinter Friendly Version
01/27/15Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple MyelomaPrinter Friendly Version
01/27/15Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70Printer Friendly Version
01/22/15Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial ResultsPrinter Friendly Version